跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,776 条关于
“Immunovant Sciences”
全部
4,776
临床试验
417
药物
562
机构
575
资讯
3,222
去年
Graves' Disease and Graft-versus-Host Disease: Pipeline Therapeutics Update
去年
Graves Disease Pipeline Shows Promise with 10+ Therapies in Development as TED Treatments Gain Regulatory Momentum
去年
Rheumatoid Arthritis Market Set to Reach $34.7 Billion by 2035, Driven by Novel Therapies and Rising Obesity Rates
2年前
Immunovant's Batoclimab Shows Promise in Graves' Disease Phase II Trial; IMVT-1402 Pivotal Trial Planned
去年
Immunovant Advances IMVT-1402 with Multiple IND Clearances and New Rheumatoid Arthritis Program
去年
Immunovant Shifts Focus to Next-Gen Therapy Despite Positive Phase III Results for Batoclimab in Myasthenia Gravis
去年
Immunovant Halts Regulatory Plans for Rare Disease Drug Despite Phase 3 Success
2年前
Immunovant's IMVT-1402 Shows Promise in Graves' Disease Treatment
5个月前
Immunovant's Batoclimab Fails Phase 3 Thyroid Eye Disease Trials Despite Early Promise
去年
Immunovant's Batoclimab Shows Promise in Phase 3 Myasthenia Gravis Trial, Analysts Maintain Strong Buy Rating
第 1 页,共 323 页
上一页
下一页